Cover Image
市場調查報告書

興和 - 產品平台分析

Kowa Company, Ltd. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 214154
出版日期 內容資訊 英文 53 Pages
訂單完成後即時交付
價格
Back to Top
興和 - 產品平台分析 Kowa Company, Ltd. - Product Pipeline Review - 2016
出版日期: 2016年08月17日 內容資訊: 英文 53 Pages
簡介

興和是總公司設立於日本的多元化經營企業,正在從事纖維,機器,建築材料,藥品,醫療設備,節能產品等的開發·製造與銷售。

本報告提供興和的治療藥開發平台的現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

興和 基本資料

  • 興和 概要
  • 主要資訊
  • 企業資料

興和 :R&D概要

  • 主要的治療範圍

興和 :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

興和 :開發中產品概況

  • 後期階段產品開發中產品
    • 登記申請前的產品/聯合治療模式
    • 第Ⅲ階段的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第Ⅱ階段的產品/聯合治療模式
    • 第Ⅰ階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式
  • 開發階段不明的開發中產品
    • 開發階段不明的產品/聯合治療模式

興和 :藥物簡介

  • pitavastatin
  • anagliptin
  • K-103IP
  • K-877
  • peretinoin
  • K-134
  • pitavastatin CR
  • ripasudil
  • epirubicin hydrochloride
  • K-312
  • Small Molecule to Inhibit Acyl-Coenzyme A for Undisclosed Indication
  • Small Molecule for Oncology
  • K-163SZ

興和 :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

興和 :最新的開發平台資訊

興和 :開發暫停中的計劃

興和 :企業理念

興和 :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08120CDB

Summary

Global Markets Direct's, 'Kowa Company, Ltd. - Product Pipeline Review - 2016', provides an overview of the Kowa Company, Ltd.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Kowa Company, Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Kowa Company, Ltd.
  • The report provides overview of Kowa Company, Ltd. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Kowa Company, Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Kowa Company, Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Kowa Company, Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Kowa Company, Ltd.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Kowa Company, Ltd.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Kowa Company, Ltd. Snapshot
    • Kowa Company, Ltd. Overview
    • Key Information
    • Key Facts
  • Kowa Company, Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Kowa Company, Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Kowa Company, Ltd. - Pipeline Products Glance
    • Kowa Company, Ltd. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Kowa Company, Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Kowa Company, Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • Kowa Company, Ltd. - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Kowa Company, Ltd. - Drug Profiles
    • pemafibrate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • anagliptin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • peretinoin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • K-134
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ripasudil
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • epirubicin hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • K-312
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pitavastatin NP
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Agonize LXRB for Atherosclerosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Acyl-Coenzyme A for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • K-163SZ
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Kowa Company, Ltd. - Pipeline Analysis
    • Kowa Company, Ltd. - Pipeline Products by Target
    • Kowa Company, Ltd. - Pipeline Products by Route of Administration
    • Kowa Company, Ltd. - Pipeline Products by Molecule Type
    • Kowa Company, Ltd. - Pipeline Products by Mechanism of Action
  • Kowa Company, Ltd. - Recent Pipeline Updates
  • Kowa Company, Ltd. - Dormant Projects
  • Kowa Company, Ltd. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • pitavastatin CR
  • Kowa Company, Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Kowa Company, Ltd., Key Information
  • Kowa Company, Ltd., Key Facts
  • Kowa Company, Ltd. - Pipeline by Indication, 2016
  • Kowa Company, Ltd. - Pipeline by Stage of Development, 2016
  • Kowa Company, Ltd. - Monotherapy Products in Pipeline, 2016
  • Kowa Company, Ltd. - Partnered Products in Pipeline, 2016
  • Kowa Company, Ltd. - Partnered Products/ Combination Treatment Modalities, 2016
  • Kowa Company, Ltd. - Pre-Registration, 2016
  • Kowa Company, Ltd. - Phase III, 2016
  • Kowa Company, Ltd. - Phase II, 2016
  • Kowa Company, Ltd. - Phase I, 2016
  • Kowa Company, Ltd. - Preclinical, 2016
  • Kowa Company, Ltd. - Discovery, 2016
  • Kowa Company, Ltd. - Unknown, 2016
  • Kowa Company, Ltd. - Pipeline by Target, 2016
  • Kowa Company, Ltd. - Pipeline by Route of Administration, 2016
  • Kowa Company, Ltd. - Pipeline by Molecule Type, 2016
  • Kowa Company, Ltd. - Pipeline Products by Mechanism of Action, 2016
  • Kowa Company, Ltd. - Recent Pipeline Updates, 2016
  • Kowa Company, Ltd. - Dormant Developmental Projects,2016
  • Kowa Company, Ltd. - Discontinued Pipeline Products, 2016
  • Kowa Company, Ltd., Other Locations
  • Kowa Company, Ltd., Subsidiaries

List of Figures

  • Kowa Company, Ltd. - Pipeline by Top 10 Indication, 2016
  • Kowa Company, Ltd. - Pipeline by Stage of Development, 2016
  • Kowa Company, Ltd. - Monotherapy Products in Pipeline, 2016
  • Kowa Company, Ltd. - Partnered Products in Pipeline, 2016
  • Kowa Company, Ltd. - Pipeline by Top 10 Target, 2016
  • Kowa Company, Ltd. - Pipeline by Route of Administration, 2016
  • Kowa Company, Ltd. - Pipeline by Molecule Type, 2016
  • Kowa Company, Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top